Published on 4 Mar 2024 on Zacks via Yahoo Finance
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
Shares of Arcturus Therapeutics Holdings Inc. ARCT have surged 73% in the past three months compared with the industry’s growth of 10.5%.
Last month, the European Commission granted orphan medicinal product designation to the company’s product candidate ARCT-032 for the treatment of cystic fibrosis (CF). The designation is likely to support the development of ARCT-032, including certain protocol assistance, access to the centralized authorization procedure, exemption from fees and research funding, along with 10 years of market exclusivity upon potential approval.
Earlier in November 2023, the FDA granted an Orphan Drug designation to ARCT-032 for the treatment of CF.